US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

KZIA

Kazia Therapeutics (KZIA)

Kazia Therapeutics Ltd

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:KZIA

1 2 3 4 5 6 7 8 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
01/05/2024	07:45	PR Newswire (US)	KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS	NASDAQ:KZIA	Kazia Therapeutics Ltd
21/03/2024	07:52	PR Newswire (US)	Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases	NASDAQ:KZIA	Kazia Therapeutics Ltd
13/03/2024	07:00	PR Newswire (US)	Kazia announces presentation of new data at AACR Annual Meeting	NASDAQ:KZIA	Kazia Therapeutics Ltd
21/02/2024	15:19	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:KZIA	Kazia Therapeutics Ltd
21/02/2024	08:19	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:KZIA	Kazia Therapeutics Ltd
21/02/2024	06:30	PR Newswire (US)	Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint	NASDAQ:KZIA	Kazia Therapeutics Ltd
14/02/2024	14:41	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:KZIA	Kazia Therapeutics Ltd
05/02/2024	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:KZIA	Kazia Therapeutics Ltd
18/01/2024	06:30	PR Newswire (US)	KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS	NASDAQ:KZIA	Kazia Therapeutics Ltd
15/12/2023	16:26	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	NASDAQ:KZIA	Kazia Therapeutics Ltd
15/12/2023	15:49	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:KZIA	Kazia Therapeutics Ltd
05/12/2023	17:02	PR Newswire (US)	Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering	NASDAQ:KZIA	Kazia Therapeutics Ltd
04/12/2023	15:05	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:KZIA	Kazia Therapeutics Ltd
01/12/2023	07:00	PR Newswire (US)	Kazia Therapeutics Announces $2 Million Registered Direct Offering	NASDAQ:KZIA	Kazia Therapeutics Ltd
29/11/2023	06:01	PR Newswire (US)	KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY	NASDAQ:KZIA	Kazia Therapeutics Ltd
21/11/2023	06:30	PR Newswire (US)	KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING	NASDAQ:KZIA	Kazia Therapeutics Ltd
20/11/2023	15:30	PR Newswire (US)	KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION	NASDAQ:KZIA	Kazia Therapeutics Ltd
15/11/2023	07:30	PR Newswire (US)	KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING	NASDAQ:KZIA	Kazia Therapeutics Ltd
10/11/2023	06:01	PR Newswire (US)	KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA	NASDAQ:KZIA	Kazia Therapeutics Ltd
01/11/2023	06:01	PR Newswire (US)	KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA	NASDAQ:KZIA	Kazia Therapeutics Ltd
26/10/2023	06:56	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:KZIA	Kazia Therapeutics Ltd
23/10/2023	06:01	PR Newswire (US)	KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY	NASDAQ:KZIA	Kazia Therapeutics Ltd
11/10/2023	06:01	PR Newswire (US)	Kazia announces voluntary delisting from ASX	NASDAQ:KZIA	Kazia Therapeutics Ltd
05/10/2023	06:01	PR Newswire (US)	KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS	NASDAQ:KZIA	Kazia Therapeutics Ltd
29/09/2023	06:01	PR Newswire (US)	KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING	NASDAQ:KZIA	Kazia Therapeutics Ltd
06/07/2023	06:00	PR Newswire (US)	KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY	NASDAQ:KZIA	Kazia Therapeutics Ltd
26/06/2023	06:01	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:KZIA	Kazia Therapeutics Ltd
08/06/2023	06:00	PR Newswire (US)	KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA	NASDAQ:KZIA	Kazia Therapeutics Ltd
25/05/2023	06:01	PR Newswire (US)	KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT	NASDAQ:KZIA	Kazia Therapeutics Ltd
14/04/2023	06:01	PR Newswire (US)	KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT	NASDAQ:KZIA	Kazia Therapeutics Ltd

Showing the most relevant articles for your search:NASDAQ:KZIA

1 2 3 4 5 6 7 8 Próxima >

BNP Paribas (QX)

Bank of America

Financial Select Sector

Verizon Communications

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones